Cover Image
市場調查報告書

Oxford BioTherapeutics Ltd:產品平台分析

Oxford BioTherapeutics Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 299292
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Oxford BioTherapeutics Ltd:產品平台分析 Oxford BioTherapeutics Ltd - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 28 Pages
簡介

Oxford BioTherapeutics Ltd是致力於開發治療癌症用抗體藥物複合體 (ADC) 的生物科技企業。

本報告提供Oxford BioTherapeutics Ltd的醫藥品開發平台現狀及各開發階段比較分析,提供您藥物簡介,藥物標的,給藥途徑,分子類型,各作用機制的藥物評估等資訊。

Oxford BioTherapeutics Ltd的基本資料

  • 概要
  • 主要資訊
  • 企業資料

Oxford BioTherapeutics Ltd:R&D概要

  • 主要的治療範圍

Oxford BioTherapeutics Ltd:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Oxford BioTherapeutics Ltd:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Oxford BioTherapeutics Ltd:藥物簡介

  • OX-001
  • MEN-1309
  • 單株抗體
  • OX-002
  • OX-003
  • OX-004

Oxford BioTherapeutics Ltd:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Oxford BioTherapeutics Ltd:最近的開發平台趨勢

Oxford BioTherapeutics Ltd:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07437CDB

Summary

Global Markets Direct's, 'Oxford BioTherapeutics Ltd - Product Pipeline Review - 2015', provides an overview of the Oxford BioTherapeutics Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oxford BioTherapeutics Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Oxford BioTherapeutics Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Oxford BioTherapeutics Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Oxford BioTherapeutics Ltd's pipeline products

Reasons to buy

  • Evaluate Oxford BioTherapeutics Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Oxford BioTherapeutics Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Oxford BioTherapeutics Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Oxford BioTherapeutics Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oxford BioTherapeutics Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Oxford BioTherapeutics Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Oxford BioTherapeutics Ltd Snapshot
    • Oxford BioTherapeutics Ltd Overview
    • Key Information
    • Key Facts
  • Oxford BioTherapeutics Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Oxford BioTherapeutics Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Oxford BioTherapeutics Ltd - Pipeline Products Glance
    • Oxford BioTherapeutics Ltd - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Oxford BioTherapeutics Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Oxford BioTherapeutics Ltd - Drug Profiles
    • OX-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MEN-1309
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 Conjugates for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates to Inhibit Tubulin for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OX-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OX-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OX-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Oxford BioTherapeutics Ltd - Pipeline Analysis
    • Oxford BioTherapeutics Ltd - Pipeline Products by Target
    • Oxford BioTherapeutics Ltd - Pipeline Products by Route of Administration
    • Oxford BioTherapeutics Ltd - Pipeline Products by Molecule Type
    • Oxford BioTherapeutics Ltd - Pipeline Products by Mechanism of Action
  • Oxford BioTherapeutics Ltd - Recent Pipeline Updates
  • Oxford BioTherapeutics Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Oxford BioTherapeutics Ltd, Key Information
  • Oxford BioTherapeutics Ltd, Key Facts
  • Oxford BioTherapeutics Ltd - Pipeline by Indication, 2015
  • Oxford BioTherapeutics Ltd - Pipeline by Stage of Development, 2015
  • Oxford BioTherapeutics Ltd - Monotherapy Products in Pipeline, 2015
  • Oxford BioTherapeutics Ltd - Out-Licensed Products in Pipeline, 2015
  • Oxford BioTherapeutics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Oxford BioTherapeutics Ltd - Phase I, 2015
  • Oxford BioTherapeutics Ltd - Preclinical, 2015
  • Oxford BioTherapeutics Ltd - Pipeline by Target, 2015
  • Oxford BioTherapeutics Ltd - Pipeline by Route of Administration, 2015
  • Oxford BioTherapeutics Ltd - Pipeline by Molecule Type, 2015
  • Oxford BioTherapeutics Ltd - Pipeline Products by Mechanism of Action, 2015
  • Oxford BioTherapeutics Ltd - Recent Pipeline Updates, 2015
  • Oxford BioTherapeutics Ltd, Subsidiaries

List of Figures

  • Oxford BioTherapeutics Ltd - Pipeline by Top 10 Indication, 2015
  • Oxford BioTherapeutics Ltd - Pipeline by Stage of Development, 2015
  • Oxford BioTherapeutics Ltd - Monotherapy Products in Pipeline, 2015
  • Oxford BioTherapeutics Ltd - Pipeline by Top 10 Molecule Type, 2015
Back to Top